Regulation of signaling by wild-type and oncogenic Ras.

Slides:

Advertisements

Similar presentations

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Advertisements

Modulation of guanine nucleotides bound to Ras by oncogenes, growth factors & GTPase activating protein JB Gibbs, MS Marshall, EM Scolnick, RA Dixon,

Cancer Chapter 16. VII. Cancer & gene regulation  A. Somatic cell mutations can =cancer  1. caused by chemical carcinogens  2. high energy radiation.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Lung Cancer Tumour Markers

Model for regulation of the Ras p21 product and for the GTPase-activating protein (GAP) as a downstream effector and regulator of ras activity. Ras is.

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

Targeting signal transduction

Hormones and Signal Transduction III

Figure 1 Cellular processes involved in cancer development

Sustaining Proliferative Signaling and Evading Growth Suppressors

MAPK pathway inhibitors.

Genetics of Cancer.

Chapter 17: Regulation of cell number

Notch1 and its role in pre-T-cell acute lymphoblastic leukemia (T-ALL)

Fas NF-κB JNK Bcl-2 Akt p21 Bax Ras TRAILR p53 EGFR TRADD Myc TNFR

Extracellular Regulation of Apoptosis

Figure 1 A schematic representation of the HER2 signalling pathway

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Nat. Rev. Nephrol. doi: /nrneph

Targeted Therapies in Melanoma: Translational Research at Its Finest

A genome-based strategy uncovers frequent BRAF mutations in melanoma

GPCR and heterotrimeric G-protein signalling.

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

mTORC1 signalling links cellular growth with autophagy

NF1 downregulation activates MAPK pathway signaling.

10.3 Regulating the Cell Cycle

The RAS/MAPK Axis Gets Stressed Out

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Oncogenic ALK signaling.

Mohammadreza Yasemi and Yaman Arkun*

Platelet-derived growth factor (PDGF) signalling pathway.

Activity flow of PDGFR signaling pathways.

The RAS-MEK-ERK pathway represents a chain of protein signalling pathway that responds to a mitogen binding to a cell surface receptor. The RAS-MEK-ERK.

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Model of Shp2-Ras-Sprouty2 signaling in lens and lacrimal gland development. Model of Shp2-Ras-Sprouty2 signaling in lens and lacrimal gland development.

The mitogen-activated protein kinase (MAPK) pathway showing mutations identified in pulmonary Langerhans cell histiocytosis (PLCH). The mitogen-activated.

Mutant BRAF Melanomas—Dependence and Resistance

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

Signaling by Ras/Raf/ERK in the regulation of β-cell proliferation.

Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.

BCR–ABL kinase activity rewires GM-CSFR signaling and confers oncogene addiction in TF1 cells. BCR–ABL kinase activity rewires GM-CSFR signaling and confers.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Regulation of p53 by MDM2. p53 and MDM2 form an autoregulatory feedback loop. p53 stimulates the expression of MDM2; MDM2, in turn, inhibits p53 activity.

OPCML-associated RTK modulation affects downstream signaling.

PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Oncogenic indel hotspots.

EGFR and cetuximab sensitivity of SCCUAT

RAS activation RAS activation (A) RAS is bound to GDP in the inactive state. Signal transduction can lead to the activation of RAS, via a GEF (GDP/GTP.

Simplified BRAF signaling network.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

OPCML directly interacts with the extracellular domain of EPHA2, FGFR1, and HER2, a prerequisite for downregulation. OPCML directly interacts with the.

TYK2 signaling in T-ALL. TYK2 signaling in T-ALL. TYK2 activates STAT1 through phosphorylation downstream of the IL-10 receptor. Once phosphorylated, STAT.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Rapid nucleotide exchange allows irreversible interactions between GDP-bound KRASG12C (middle) and ARS-853 (right). Rapid nucleotide exchange allows irreversible.

An overview of the MAPK signaling pathway with points of therapeutic intervention indicated. An overview of the MAPK signaling pathway with points of therapeutic.

Wild-type and oncogenic Ras differentially regulate cell proliferation

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

Turning Reciprocal Feedback Regulation into Combination Therapy

Inhibition of BCR-mediated signaling by ARQ 531.

Genotype-specific combinatorial drug sensitivities in melanoma.

Presentation transcript:

Regulation of signaling by wild-type and oncogenic Ras. Regulation of signaling by wild-type and oncogenic Ras. Oncogenic Ras is constitutively GTP bound and regulates basal MAPK signaling. Growth factor receptors and negative regulatory proteins such as EGFR and EphA2, respectively, modulate wild-type Ras activity and in turn affect downstream signaling. In the basal state, wild-type Ras, which is predominantly GDP bound, inhibits oncogenic Ras signaling. Oncogenic Ras negatively regulates EGFR sensitivity. Suppression of basal MAPK signaling, via depletion of oncogenic Ras or pharmacologic inhibition of MEK, relieves this negative feedback and sensitizes cells to EGF stimulation. Amy Young et al. Cancer Discovery 2013;3:112-123 ©2013 by American Association for Cancer Research